FDA Panel to Consider Which COVID Strain to Target in an Updated Vaccine

Source link :

The current predominant strain of COVID-19 should be a key consideration during the upcoming meeting of an FDA advisory committee tasked with making recommendations about the next COVID vaccine, agency staff said in a briefing document released Monday. “Although JN.1 sublineages were predominant through spring 2024 in the U.S., the KP.2 subvariant has now become […]

Author : News Health

Publish date : 2024-06-03 21:07:12

Copyright for syndicated content belongs to the linked Source.